SG182159A1 - Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma - Google Patents

Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma Download PDF

Info

Publication number
SG182159A1
SG182159A1 SG2012040960A SG2012040960A SG182159A1 SG 182159 A1 SG182159 A1 SG 182159A1 SG 2012040960 A SG2012040960 A SG 2012040960A SG 2012040960 A SG2012040960 A SG 2012040960A SG 182159 A1 SG182159 A1 SG 182159A1
Authority
SG
Singapore
Prior art keywords
seq
marker
glaucoma
allele
markers
Prior art date
Application number
SG2012040960A
Other languages
English (en)
Inventor
Gudmar Thorleifsson
Kristinn P Magnusson
Original Assignee
Decode Genetics Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf filed Critical Decode Genetics Ehf
Publication of SG182159A1 publication Critical patent/SG182159A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG2012040960A 2007-06-13 2008-06-13 Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma SG182159A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS8651 2007-06-13
IS8664 2007-07-13
IS8668 2007-08-08

Publications (1)

Publication Number Publication Date
SG182159A1 true SG182159A1 (en) 2012-07-30

Family

ID=39869955

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012040960A SG182159A1 (en) 2007-06-13 2008-06-13 Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma

Country Status (12)

Country Link
US (1) US20090035279A1 (enExample)
EP (1) EP2179062A2 (enExample)
JP (1) JP2010533477A (enExample)
KR (1) KR20100037592A (enExample)
CN (1) CN101784675B (enExample)
AU (1) AU2008263384B2 (enExample)
CA (1) CA2690671A1 (enExample)
IL (1) IL202674A0 (enExample)
MX (1) MX2009013649A (enExample)
NZ (1) NZ582131A (enExample)
SG (1) SG182159A1 (enExample)
WO (1) WO2008152656A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004404A1 (en) * 2009-07-10 2011-01-13 Decode Genetics Ehf Genetic variants for predicting risk of glaucoma
SG10201407330UA (en) 2009-11-16 2015-01-29 Agency Science Tech & Res Obtaining data for automatic glaucoma screening, and screening and diagnostic techniques and systems using the data
US20110195457A1 (en) * 2010-02-09 2011-08-11 General Electric Company Isothermal amplification of nucleic acid using primers comprising a randomized sequence and specific primers and uses thereof
GB201021457D0 (en) * 2010-12-17 2011-02-02 Univ Manchester Anti-ageing agents
CA2833165A1 (en) * 2011-04-14 2012-10-18 Complete Genomics, Inc. Processing and analysis of complex nucleic acid sequence data
US8718950B2 (en) 2011-07-08 2014-05-06 The Medical College Of Wisconsin, Inc. Methods and apparatus for identification of disease associated mutations
RU2495420C1 (ru) * 2012-10-11 2013-10-10 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезний имени Гельмгольца" Министерства здравоохранения и социального развития Российской Федерации Способ дифференциальной диагностики раноприобретенной и врожденной прогрессирующей миопии
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
KR102465122B1 (ko) 2016-02-12 2022-11-09 리제너론 파마슈티칼스 인코포레이티드 비정상적인 핵형을 검출하기 위한 방법 및 시스템
WO2018003523A1 (ja) * 2016-06-30 2018-01-04 京都府公立大学法人 広義原発開放隅角緑内障の発症リスクの判定方法
CN106529558B (zh) * 2016-10-28 2019-05-24 北京化工大学 青光眼图像特征提取方法及装置
CN106978509B (zh) * 2017-06-07 2018-10-26 中南大学湘雅二医院 青光眼诊断分子标记物lncRNAs ENST00000607393、试剂盒及应用
CN110272996A (zh) * 2019-07-31 2019-09-24 汶上县中医院 与青光眼发生发展相关的生物标志物及其应用
EP4110465A4 (en) * 2020-02-24 2024-06-12 The Board Of Regents Of The University Of Texas System MOLECULAR BIOMARKERS AND TARGETS FOR FUCHS ENDOTHELIAL CORNEAL DYSTROPHY AND GLAUCOMA
CN112684186B (zh) * 2020-12-31 2022-04-01 华中科技大学 用于预测2型糖尿病患者发生mci风险的生物标志物和试剂盒及其应用
CN113430263B (zh) * 2021-08-27 2021-11-05 中国医学科学院北京协和医院 基于生物标志物的诊断青光眼的产品及其应用
CN115691662B (zh) * 2022-11-08 2023-06-23 温州谱希医学检验实验室有限公司 基于变构概率对近视/高度近视相关snp风险的排序方法和系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197621A (en) * 1960-12-30 1965-07-27 Ibm Real time control system for processing main and incremental quantities
US3705942A (en) * 1969-09-29 1972-12-12 Ciba Geigy Corp Treatment of glaucoma employing imipramine or desmethylimipramine
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
CA2217097A1 (en) * 1997-09-30 1999-03-30 Jean-Louis Anctil Molecular diagnostic of glaucomas associated with chromosomes 2 and 6
JP2002306165A (ja) * 2000-05-17 2002-10-22 Tsubota:Kk 正常眼圧緑内障を含む開放隅角緑内障の関連遺伝子
US20040091914A1 (en) * 2002-08-02 2004-05-13 Sysmex Corporation Gene assay method for predicting glaucoma onset risk
WO2005069975A2 (en) * 2004-01-23 2005-08-04 Massachusetts Eye & Ear Infirmary Lysyl oxidase-like 1 (loxl1) and elastogenesis
US20060134172A1 (en) * 2004-12-21 2006-06-22 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies

Also Published As

Publication number Publication date
IL202674A0 (en) 2011-08-01
MX2009013649A (es) 2010-01-27
AU2008263384B2 (en) 2014-08-28
CA2690671A1 (en) 2008-12-18
EP2179062A2 (en) 2010-04-28
NZ582131A (en) 2012-07-27
KR20100037592A (ko) 2010-04-09
CN101784675B (zh) 2014-10-29
WO2008152656A2 (en) 2008-12-18
JP2010533477A (ja) 2010-10-28
AU2008263384A1 (en) 2008-12-18
WO2008152656A3 (en) 2009-02-05
US20090035279A1 (en) 2009-02-05
CN101784675A (zh) 2010-07-21

Similar Documents

Publication Publication Date Title
SG182159A1 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
Deltas et al. Molecular genetics of familial hematuric diseases
SG178811A1 (en) Genetic susceptibility variants associated with cardiovascular disease
Ebermann et al. PDZD7 is a modifier of retinal disease and a contributor to digenic Usher syndrome
Lekszas et al. Biallelic TANGO1 mutations cause a novel syndromal disease due to hampered cellular collagen secretion
Bowne et al. A dominant mutation in RPE65 identified by whole-exome sequencing causes retinitis pigmentosa with choroidal involvement
de La Hoya et al. Combined genetic and splicing analysis of BRCA1 c.[594-2A> C; 641A> G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms
AU2008231425B2 (en) Genetic variants on Chr2 and Chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
Dixon et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking
McLean et al. An unusual N-terminal deletion of the laminin α3a isoform leads to the chronic granulation tissue disorder laryngo-onycho-cutaneous syndrome
SG177185A1 (en) Genetic markers for risk management of cardiac arrhythmia
Whiteman et al. Defective secretion of recombinant fragments of fibrillin-1: implications of protein misfolding for the pathogenesis of Marfan syndrome and related disorders
Bentivegna et al. Rubinstein-Taybi Syndrome: spectrum of CREBBP mutations in Italian patients
US8865400B2 (en) Genetic variants contributing to risk of prostate cancer
Sharma et al. Association of genetic variants in the TMCO1 gene with clinical parameters related to glaucoma and characterization of the protein in the eye
Miyamoto et al. Identification of a novel splice site mutation of the CSPG2 gene in a Japanese family with Wagner syndrome
Avila-Fernandez et al. Whole-exome sequencing reveals ZNF408 as a new gene associated with autosomal recessive retinitis pigmentosa with vitreal alterations
Permanyer et al. Autosomal recessive retinitis pigmentosa with early macular affectation caused by premature truncation in PROM1
Hull et al. Nonsyndromic retinal dystrophy due to bi-allelic mutations in the ciliary transport gene IFT140
Willoughby et al. Defining the pathogenicity of optineurin in juvenile open-angle glaucoma
Soens et al. Leveraging splice‐affecting variant predictors and a minigene validation system to identify Mendelian disease‐causing variants among exon‐captured variants of uncertain significance
EP2257298A2 (en) Genetic polymorphisms associated with stroke, methods of detection and uses thereof
Zhang et al. Whole-exome sequencing revealed HKDC1 as a candidate gene associated with autosomal-recessive retinitis pigmentosa
Nyegaard et al. A novel locus harbouring a functional CD164 nonsense mutation identified in a large danish family with nonsyndromic hearing impairment
Azuma et al. Integrator complex subunit 15 controls mRNA splicing and is critical for eye development